EssilorLuxottica acquires Canadian startup Cellview Imaging

News
Article

Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, according to a news release.

Men at desk making business deal Image credit: AdobeStock/Panumas

Image credit: AdobeStock/Panumas

EssilorLuxottica has announced its acquisition of Cellview Imaging, a Canadian startup specializing in innovative diagnostic via retinal imaging.1 By joining forces, the companies will plan on building a wider portfolio of ophthalmic instruments and solutions within the med-tech space, according to a news release.

“We are happy to welcome Cellview’s team to EssilorLuxottica and to work together to accelerate our strategy in vision health,” said a joint statement from Francesco Milleri, chairman and CEO, and Paul du Saillant, deputy CEO, of EssilorLuxottica, in the release. “By integrating another pioneering company with strong expertise in R&D and world class imaging solutions, we will provide a comprehensive portfolio of innovative technologies to the ophthalmic care community to better address the growing need of vision health and the early diagnosis of retinal pathologies. While our products and services remain accessible to all industry players – as a pillar of EssilorLuxottica’s open business model – we continue to elevate market standards, in full alignment with our journey into the med-tech space.”

Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, which are distributed in North America.1 The company’s device, WRI-1,2 allows eye care providers to diagnose retinal pathologies with an ultra-widefield retinal camera that captures larger images compared to most devices on the market, according to the release. The diagnostic tool produces an image up to 133 degrees in a single capture, or 200 degrees in an automated 2 image auto-stitched. WRI-1 penetrates to the deepest layers of the eye through cataracts, small pupils, and other media opacities.2

Cellview’s product offering is FDA and CE approved, with a market base ranging from eye care practices, retail locations, and ophthalmology clinics. Cellview is looking to broaden its distribution to different geographies, starting with Europe.1

References:
  1. EssilorLuxottica acquires the Candian med-tech startup Cellview. News release. EssilorLuxottica. February 11, 2025. Accessed February 11, 2025.
  2. Welcome to the future of retinal imaging. Cellview Imaging. Accessed February 11, 2025. https://cellviewimaging.com/en-us

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
© 2025 MJH Life Sciences

All rights reserved.